The Danish pharmaceutical giant Novo Nordisk is navigating a period of significant pressure from two distinct fronts. Investors are grappling with a subdued long-term financial outlook issued by the company, while simultaneously, it has initiated a major patent infringement lawsuit in the United States.
Subdued Long-Term Guidance Disappoints the Market
In early February, Novo Nordisk provided its financial expectations for the year 2026, forecasting a decline in both revenue and operating profit. The company attributed this projected slowdown to anticipated lower selling prices for its products in the U.S. market and the impending loss of exclusivity for certain medicines in international territories. This guidance followed a report of solid performance for 2025, during which sales grew by 10% at constant exchange rates.
The market’s reaction to the 2026 forecast was pronounced. The company’s share price experienced a noticeable drop following the announcement, indicating that investor expectations had been set for a more optimistic assessment of future growth.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Share Buyback Program Launched Amid Challenges
Concurrent with its cautious forward-looking statements, Novo Nordisk’s board authorized a new share repurchase initiative. The program, set to commence on February 4, will run for a twelve-month period with the aim of buying back shares worth up to 15 billion Danish kroner. This move is widely interpreted as a signal of the management’s confidence in the firm’s long-term strategic direction, even in the face of near-term headwinds.
Patent Lawsuit Filed Against U.S. Telehealth Provider
Adding to the current climate, Novo Nordisk filed a lawsuit on Monday against the American telemedicine company Hims & Hers Health. The legal action alleges patent infringement related to weight-loss medications. According to the filing, Hims & Hers had previously launched copycat versions of Novo Nordisk’s obesity treatments. The suit covers both tablet and injectable formulations, underscoring the pharmaceutical leader’s aggressive stance on defending its intellectual property portfolio in a highly competitive market segment.
Key Upcoming Events for Investors
Shareholders will have several opportunities in the coming months to gauge the company’s progress. The Annual General Meeting is scheduled for March 26. This will be followed by the release of the Q1 2026 financial results on May 6, the half-year report on August 5, and the Q3 figures on November 4. These milestones will be critical in demonstrating whether Novo Nordisk can maintain its trajectory in the fiercely contested markets for diabetes and obesity therapies.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from February 10 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 10.
Novo Nordisk: Buy or sell? Read more here...
